A MEK inhibitor drug which started life as a Pfizer Inc. oncology candidate might be an effective antiviral therapy against coronavirus 2019-nCoV.
Atriva Therapeutics GmbH is a start-up pharma company based in Tübingen, Germany, and is developing its lead candidate ATR-002 for use as a novel antiviral treatment for seasonal